KASL clinical practice guidelines for management of chronic hepatitis B

,

doi:10.3350/cmh.2022.0084

Cited by 61 publications

(29 citation statements)

References 481 publications

(544 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In South Korea, a nationwide cancer screening program has been implemented and credited with enhancing the outcomes of patients with HCC over the last two decades ( 21 , 22 ). This program has shown that HBV-induced HCC is highly prevalent, yet compliance with the screening program has been suboptimal ( 23 ). Targeted screening programs for high-risk cohorts could increase the treatment rates and enhance the outlook of individuals with HCC.…”

Section: Discussionmentioning

confidence: 99%

“…These factors may explain why our pool of patients chose not to be treated but considering our retrospective characteristic of our study, it in an inevitable limitation. In South Korea, a nationwide cancer screening program has been and credited with enhancing the outcomes of patients with HCC over the last two decades (21,22). This program has shown that HBVinduced HCC is highly prevalent, yet compliance with the screening program has been suboptimal (23).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Factors associated with the survival outcomes of patients with untreated hepatocellular carcinoma: An analysis of nationwide data

et al. 2023

View full text Add to dashboard Cite

IntroductionIn this study, we examined the natural course of untreated hepatocellular carcinoma (HCC) and identified predictors of survival in an area where hepatitis B is the predominant cause of HCC.MethodsWe identified 1,045 patients with HCC who did not receive HCC treatment and were registered in the Korean Primary Liver Cancer Registry between 2008 and 2014, and were followed-up up to December 2018. Thereafter, we analyzed the clinical characteristics of patients who survived for <12 or ≥12 months. A Cox proportional regression model was used to identify the variables associated with patient survival.Results and discussionThe mean age of the untreated patients at HCC diagnosis was 59.6 years, and 52.1% of patients had hepatitis B. Most untreated patients (94.2%) died during the observation period. The median survival times for each Barcelona Clinic Liver Cancer (BCLC) stage were as follows: 31.0 months for stage 0/A (n = 123), 10.0 months for stage B (n = 96), 3.0 months for stage C (n = 599), and 1.0 month for stage D (n = 227). Multivariate Cox regression analysis demonstrated that BCLC stage D (hazard ratio, 4.282; P < 0.001), model for end-stage liver disease (MELD) score ≥10 (HR, 1.484; P < 0.001), and serum alpha-fetoprotein (AFP) level ≥1,000 ng/mL (HR, 1.506; P < 0.001) were associated with poor survival outcomes in patients with untreated HCC. In untreated patients with HCC, advanced stage BCLC, serum AFP level ≥1,000 ng/mL, and MELD score ≥10 were significantly associated with overall survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Factors associated with the survival outcomes of patients with untreated hepatocellular carcinoma: An analysis of nationwide data

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In this retrospective study, 217 patients with advanced HCC who were treated with lenvatinib as a first-line systemic therapy at Samsung Medical Center between October 2018 and October 2020 were screened as potential eligible patients. The diagnosis of HCC was made histologically or clinically in accordance with the regional HCC guidelines 21 , 22 . Patients were excluded if they met any of the following criteria (n = 101): (i) concurrent therapy with other systemic agents or radioembolization; (ii) unusual dosing regimens or frequent dose modifications due to poor drug adherence; (iii) discontinuation of lenvatinib before the 1 st treatment response assessment (i.e., refusal of further treatment, follow-up loss, deterioration of performance status or liver function, infection, severe adverse events (AEs)); (iv) baseline liver function of Child–Pugh score ≥ 7; or (v) absence of valid baseline computed tomography (CT) image.…”

Section: Methodsmentioning

confidence: 99%

Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy

Goh

Kang

Jeong

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Cancer cachexia affects quality of life, response to chemotherapy, and survival in many advanced cancer patients. The aim of this study was to evaluate the prognostic value of pretreatment cachexia index (CXI) in patients with advanced hepatocellular carcinoma (HCC) treated with systematic chemotherapy. Patients with advanced HCC treated with lenvatinib therapy between October 2018 and October 2020 were retrospectively studied. The CXI was calculated as (L3 skeletal muscle index) × (serum albumin)/(neutrophil-to-lymphocyte ratio). The association with treatment response and early adverse events within the first two months of lenvatinib therapy was investigated. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier method with log-rank test. Multivariable Cox regression was used to identify the predictors of survival. A total of 116 patients (median age: 60, male: 84.5% ) with calculated CXI. They divided into two groups: high CXI (≥ 53, n = 82) and low CXI (< 53, n = 34). Patients with low CXI had a significantly lower disease control rate (61.8% vs. 89.0%, p = 0.001) and a shorter median OS (8.0 [95% CI 6.2–9.8] vs. 12.3 [95% CI 10.1–14.4] months, p = 0.002) than those with high CXI. In multivariable analysis, low CXI was independently associated with shorter OS (HR: 2.07, 95% CI: 1.17–3.65, p = 0.01) and PFS (HR: 1.84, 95% CI: 1.09–3.09, p = 0.02). Of note, during the first two months of lenvatinib therapy, anorexia (41.2% vs. 22.0%, p = 0.04) developed more frequently among patients with low CXI than those with high CXI. The CXI may be a clinically useful index for predicting poor treatment response and prognosis in patients with advanced HCC undergoing lenvatinib treatment.

show abstract

“…Therefore, the inhibition of HBV or HCV proliferation by antiviral therapy is expected to reduce the incidence of HCC. Regarding the antiviral therapy of chronic hepatitis B and chronic hepatitis C, we recommend following the clinical practice guidelines of the Korean Association for the Study of Liver (KASL) [ 45 46 ].…”

Section: Preventionmentioning

confidence: 99%

2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

2022

Korean J Radiol

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is high in middle and old age. The current practice guidelines will provide useful and sensible advice for the clinical management of patients with HCC. A total of 49 experts in the fields of hepatology, oncology, surgery, radiology, and radiation oncology from the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions. These guidelines provide useful information and direction for all clinicians, trainees, and researchers in the diagnosis and treatment of HCC.

show abstract

KASL clinical practice guidelines for management of chronic hepatitis B

Cited by 61 publications

References 481 publications

Factors associated with the survival outcomes of patients with untreated hepatocellular carcinoma: An analysis of nationwide data

Factors associated with the survival outcomes of patients with untreated hepatocellular carcinoma: An analysis of nationwide data

Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy

2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

Contact Info

Product

Resources

About